rVSVΔG-ZEBOV-GP

also known as ERVEBO · V920

Developed for: Ebola hemorrhagic fever
Investigated by: Centre de Recherche Médicale de Lambaréné · Epicentre · European and Developing Countries Clinical Trials Partnership (EDCTP) · French National Institute of Health and Medical Research · London School of Hygiene and Tropical Medicine · Medecins Sans Frontieres, Netherlands
+3 more
· Merck Sharp & Dohme LLC · National Institute of Allergy and Infectious Diseases (NIAID) · Partnership for Research on Ebola Virus in Liberia (PREVAIL)

2017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT05130398	Apr → Sep 2021	Ebola hemorrhagic fever	Centre de Recherche Médicale de Lambaréné	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT02876328	Mar 2017 → Dec 2019	Ebola hemorrhagic fever	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT03161366	May → Jul 2018	Ebola hemorrhagic fever	Epicentre	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	rVSVΔG-ZEBOV-GP	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876328 ↗ 2 NCT03161366 ↗ NCT05130398 ↗
Known as	ERVEBO	“The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated for the prevention of Ebola virus disease...” PMID 37967326 ↗ Apr 2024
Known as	V920	“Biological: rVSVΔG-ZEBOV-GP, V920” NCT05130398 ↗
Modality	Vaccine	“The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine” PMID 37967326 ↗ Apr 2024
Route	Intramuscular	“Participants of the experimental arm will receive a single intramuscular dose of ≥7.8 x 107 pfu of the rVSVΔG-ZEBOV-GP vaccine.” NCT05130398 ↗